MEDI-551 Treatment Effectively Depletes B Cells and Reduces Serum Titers of Autoantibodies in Mice Transgenic forSle1and Human CD19

A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow

(2015) H. E. Mei et al.   BLOOD

Suppression of Fcγ-Receptor-Mediated Antibody Effector Function during Persistent Viral Infection

(2015) Douglas H. Yamada et al.   IMMUNITY

Antibody Effector Functions Mediated by Fcγ-Receptors Are Compromised during Persistent Viral Infection

(2015) Andreas Wieland et al.   IMMUNITY

B10 Cells: A Functionally Defined Regulatory B Cell Subset

(2015) Thomas F. Tedder   JOURNAL OF IMMUNOLOGY

CD19 as a molecular target in CNS autoimmunity

(2014) Olaf Stüve et al.   ACTA NEUROPATHOLOGICA

The efficacy of novel B cell biologics as the future of SLE treatment: A review

(2014) Ameer Kamal et al.   AUTOIMMUNITY REVIEWS

Single Dose of Glycoengineered Anti-CD19 Antibody (MEDI551) Disrupts Experimental Autoimmune Encephalomyelitis by Inhibiting Pathogenic Adaptive Immune Responses in the Bone Marrow and Spinal Cord while Preserving Peripheral Regulatory Mechanisms

(2014) Ding Chen et al.   JOURNAL OF IMMUNOLOGY

Lasting Antibody Responses Are Mediated by a Combination of Newly Formed and Established Bone Marrow Plasma Cells Drawn from Clonally Distinct Precursors

(2014) Irene Chernova et al.   JOURNAL OF IMMUNOLOGY

IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases

(2014) Ping Shen et al.   NATURE

Interleukin-35 induces regulatory B cells that suppress autoimmune disease

(2014) Ren-Xi Wang et al.   NATURE MEDICINE

The BAFF/APRIL system in SLE pathogenesis

(2014) Fabien B. Vincent et al.   Nature Reviews Rheumatology

Germinal Center B Cell Depletion Diminishes CD4+ Follicular T Helper Cells in Autoimmune Mice

(2014) Isharat Yusuf et al.   PLoS One

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

(2013) Daniel J Wallace et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double-Blind, Phase III Study

(2013) Eduardo F. Mysler et al.   ARTHRITIS AND RHEUMATISM

Belimumab for Systemic Lupus Erythematosus

(2013) Bevra Hannahs Hahn   NEW ENGLAND JOURNAL OF MEDICINE

Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006

(2013) V. Strand et al.   RHEUMATOLOGY

B-cell targeted therapeutics in clinical development

(2013) Stephan Blüml et al.   ARTHRITIS RESEARCH & THERAPY

The Plasma Cell Signature in Autoimmune Disease

(2013) Katie Streicher et al.   Arthritis & Rheumatology

Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial

(2012) William Stohl et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study

(2012) Brad H. Rovin et al.   ARTHRITIS AND RHEUMATISM

Homing and Adhesion Patterns Determine the Cellular Composition of the Bone Marrow Plasma Cell Niche

(2012) E. Belnoue et al.   JOURNAL OF IMMUNOLOGY

Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity

(2012) Henrik E Mei et al.   ARTHRITIS RESEARCH & THERAPY

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

(2011) Richard Furie et al.   ARTHRITIS AND RHEUMATISM

A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo

(2011) Elizabeth Ward et al.   BRITISH JOURNAL OF HAEMATOLOGY

Six color flow cytometry detects plasma cells expressing aberrant immunophenotype in bone marrow of healthy donors

(2011) Valdas Peceliunas et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

B Lymphocytes Differentially Influence Acute and Chronic Allograft Rejection in Mice

(2011) D. J. DiLillo et al.   JOURNAL OF IMMUNOLOGY

An Acquired Defect in IgG-Dependent Phagocytosis Explains the Impairment in Antibody-Mediated Cellular Depletion in Lupus

(2011) A. Ahuja et al.   JOURNAL OF IMMUNOLOGY

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

(2011) Sandra V Navarra et al.   LANCET

Eosinophils are required for the maintenance of plasma cells in the bone marrow

(2011) Van Trung Chu et al.   NATURE IMMUNOLOGY

Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus

(2010) Kai W. Bekar et al.   ARTHRITIS AND RHEUMATISM

Inflammation-independent defective early B cell tolerance checkpoints in rheumatoid arthritis

(2010) Laurence Menard et al.   ARTHRITIS AND RHEUMATISM

Megakaryocytes constitute a functional component of a plasma cell niche in the bone marrow

(2010) O. Winter et al.   BLOOD

B-lymphocyte effector functions in health and disease

(2010) David J. DiLillo et al.   IMMUNOLOGIC RESEARCH

Protective and Pathogenic Roles for B Cells during Systemic Autoimmunity in NZB/W F1 Mice

(2010) K. M. Haas et al.   JOURNAL OF IMMUNOLOGY

B-Cell Depletion In Vitro and In Vivo with an Afucosylated Anti-CD19 Antibody

(2010) R. Herbst et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

B cells as therapeutic targets in SLE

(2010) Iñaki Sanz et al.   Nature Reviews Rheumatology

Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood

(2009) Shigeru Iida et al.   BMC CANCER

CD19: a promising B cell target for rheumatoid arthritis

(2009) Thomas F. Tedder   Nature Reviews Rheumatology